This article was originally published in Start Up
With one of the discoverers of p53, David Lane, PhD as its scientific officer, Cyclacel is developing small molecule anti-cancer drugs which target the cell cycle.
You may also be interested in...
Many think that British biotech is a disaster waiting to happen. The four companies profiled in this issue are attempting to establish themselves as product-driven companies, run by professional managers.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.